FindTrial
Sign In

Hyteroscopy in abnormal uterine bleeding pateints

study of hysteroscopic evaluation in patent with AUB and its correlation with histopathology

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/05/052786
Enrollment
150
Registered
2023-05-17
Start date
Unknown
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N719- Inflammatory disease of uterus, unspecified

Interventions

None listed

Sponsors

Dr Jyoti Ahlawat
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Intermenstrual heavy bleeding (Menometrorrhagia), 2. Frequent cycles (Polymenorrhea), Infrequent menstrual bleeding (Oligomenorrhea). 3. Frequent and heavy menstrual bleeding (Polymenorrhagia), 4. Fibroid uterus 5. Uterovaginal congenital anomaly

Exclusion criteria

Exclusion criteria: 1. IUCD (Intrauterine contraceptive devices), 2. Hormone producing Ovarian tumours in USG, 3. Endocrine disorders like hyperthyroidism- or hypothyroidism, 4. Cervical malignancy 5. on medications like steroids, neuroleptics and anticoagulants,

Design outcomes

Primary

MeasureTime frame
to assess different causes of abnormal uterine bleedingTimepoint: 4 weeks—

Secondary

MeasureTime frame
to correlate hysteroscopic findings with histopathological resultsTimepoint: 8 weeks—

Countries

India

Contacts

Public ContactDr Jyoti Ahlawat

Varunarjun Medical college and rohilkhand hospital

obgyvamc@gmail.com8178751027

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026